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Anterior cingulate glutamateglutamine levels
predict symptom severity in women with
obsessivecompulsive disorder
Murat Yu¨cel, Stephen J. Wood, R. Mark Wellard, Ben J. Harrison,
Alex Fornito, Jesus Pujol, Dennis Velakoulis, Christos Pantelis
Objective: Abnormalities of the anterior cingulate cortex (ACC) have consistently been
identified in obsessivecompulsive disorder (OCD), but very few studies have examined
the biochemical basis of such changes. The purpose of the present study was to
investigate how ACC biochemistry in OCD varies as a function of gender, hemisphere,
subregion, and symptomatology.
Method: 3 TAQ5 proton-magnetic resonance spectroscopy (MRS)6 was used to probe ACC
biochemistry in 20 OCD patients (10 male, 10 female) and a comparable group of 26
healthy comparison subjects. Data were acquired from the left and right dorsal and rostral
subregions of the ACC. Metabolites assessed included N-acetylaspartate (NAA),
glutamateglutamine (Glx), choline-containing compounds (Cho), creatine/
phosphocreatine (Cr), and myoinositol-containing compounds (mI).
Results: Female OCD patients had significantly reduced levels of Glx in all but one
subregion of the ACC when compared to matched controls. Levels of Glx were correlated
with clinical measures of symptom severity in female but not male patients. State levels of
anxiety and depression did not explain this association. In addition, both male and female
OCD patients had relatively higher concentrations of mI in their right ACC (rostral and
dorsal) compared with healthy controls. No other compounds had any statistically
significant group differences, nor were the concentrations of any other compounds
correlated with symptom measures.
Conclusions: To the authors’ knowledge this is the first study to demonstrate gender-
specific neurochemical changes in OCD. Although these findings are tentative and require
replication, they raise the possibility that MRS techniques may be of use in objectively
monitoring patient progress and assessing the effectiveness of various treatments.
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Neurobiological models of obsessivecompulsive
disorder (OCD) emphasize excessive activity of
frontostriatal brain circuits, including the anterior
cingulate cortex (ACC), both at rest and during
cognitive task performance and symptom provoca-
tion [14]. But despite the fact that consistent
identification of ACC functional abnormalities have
been identified in OCD, very few studies have
examined whether there are also biochemical ab-
normalities in the region.
Proton magnetic resonance spectroscopy (1H-
MRS) offers a non-invasive means for obtaining
information about brain biochemistry in vivo, and
allows such measures to be related to the various
clinical manifestations of OCD. In this context, two
of the most widely studied metabolites have been
glutamateglutamine (Glx) and N-acetylaspartate
(NAA). Elevated Glx levels have been found in the
caudate of treatment-naı¨ve patients (both paediatric
and adult), but these seem to normalize after treat-
ment with selective-serotonin re-uptake inhibitors
(SSRIs) [59]. Similar Glx elevations have been
reported in orbitofrontal regions in adult OCD
patients [10], although Rosenberg et al. recently
found that Glx concentrations in the ACC of
paediatric OCD patients were decreased rather than
increased, even when medication-naı¨ve, suggesting
that the nature of glutamatergic pathology in this
disorder may be regionally specific [11]. Reduced
levels of NAA, considered to be a marker of neuronal
viability [12], have also been found in OCD patients
[1315] and although they also normalize with SSRI
treatment, they are not correlated with symptomato-
logical improvement [14].
Thus, although both Glx and NAA abnormalities
respond to treatment, only the former appears to be
related to symptom improvement [59]. Several
limitations of this work, however, restrict the conclu-
sions that can be drawn, particularly as they pertain
to the ACC. First, studies have varied with respect to
the side (left only, right only, or bilateral) and
subregion of the ACC sampled. Given that the
ACC is a functionally heterogeneous region [16],
subtle, regionally specific, alterations may be ob-
scured unless key subregions are assessed indepen-
dently. Second, few studies have explicitly examined
gender differences. Gender has been shown to influ-
ence both clinical and biological heterogeneity in
OCD [17], thus representing an important variable
for consideration. Finally, most studies have focused
on one or a few metabolites, and have failed to
exploit the potential of 1H-MRS to provide measures
of other markers of cellular function and integrity,
such as choline-containing metabolites (Cho; a mea-
sure of lipid turnover), creatine plus phosphocreatine
(Cr; a measure of cellular energetics) and myoinosi-
tol-containing compounds (mI; among other things,
an index of glial metabolism). There has been no
study to date that has comprehensively examined
each of these metabolites across the various subre-
gions of the ACC in OCD.
In this context we analysed data acquired from the
dorsal and rostral ACC in 20 male and female OCD
patients and 26 healthy comparison subjects. Data
from the dorsal ACC have been previously published,
although the effects of gender and hemispheric
laterality were not examined [15]. Thus, in the present
investigation we probed ACC biochemistry from the
dorsal and rostral subregions of the ACC of each
hemisphere, which are thought to be specialized for
cognitive and affective functioning, respectively [16].
Using a 3 T AQ6scanner allowed us to resolve signals
from Glx, NAA, mI, Cr and Cho, facilitating a
comprehensive in vivo assay of ACC biochemistry in
OCD.
Methods
Subjects
Twenty OCD patients and 26 healthy volunteers were recruited
from the general community through advertisements in local
newspapers and community services. All patients were required
to (i) have a current IQ of 80; (ii) be medication-free or stable on
their medication dose for at least 1 month; and (iii) have no other
current Axis I psychiatric diagnosis. All subjects with a history of
significant head injury, neurological disease, electroconvulsive
therapy, impaired thyroid function, or steroid use were excluded.
After complete description of the study to the subjects, written
informed consent was obtained. Demographic and clinical char-
acteristics of the samples are given in Table 1.
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Table 1. Subject characteristics (mean9SD)
Group Characteristics OCD Healthy Control Analyses
Male Female Total Male Female Total Group GroupGender
Gender 10 10 20 13 13 26  p0.62
Handedness (right/left) 10/0 10/0 20/0 13/0 13/0 26/0  
Age (years) 36.8099.44 32.00912.01 34.40910.83 30.3196.22 30.1598.33 30.2397.21 p0.13 p0.39
Education (years) 15.091.63 14.092.67 14.592.12 14.6292.87 15.6991.55 15.1592.33 p0.34 p0.13
IntelligenceVIQ 110.6097.63 107.9094.20 109.2596.15 109.3914.50 111.0896.64 110.27911.08 p0.72 p0.45
IntelligencePIQ 111.20914.21 108.30914.17 109.75913.89 113.31912.79 116.23910.87 114.77911.72 p0.20 p0.45
Intelligence  FSIQ 112.50910.08 108.6098.62 110.5599.34 112.77913.64 114.8598.30 113.81911.11 p0.30 p0.34
BAI 10.3098.45 10.20910.43 10.2599.24 4.3894.57 6.4696.35 5.4295.52 p0.03 p0.81
BDI-II 9.2096.58 11.20910.24 10.2098.44 5.2395.15 6.2395.58 5.7395.29 p0.03 p0.63
Clinical Measures Male Female Group Gender
Illness duration (years) 14.4912.2 12.4910.3 13.4911.0    p0.78 
YBOCSObsessions 9.6092.95 9.1093.81 9.3593.33    p0.75 
YBOCSCompulsions 10.0092.49 10.4092.41 10.2092.40    p0.72 
YBOCSTotal 19.6095.23 19.5095.68 19.5595.32    p0.97 
PIObsessional Thoughts 4.8094.83 5.9095.17 5.3594.90    p0.63 
PIObsessional
Impulses
1.4091.26 1.2092.25 1.3091.78    p0.81 
PIContamination Compul-
sion
12.40910.79 11.30910.65 11.85910.45    p0.82 
PIChecking Compulsions 13.80913.44 20.00913.79 16.90913.63    p0.32 
PIDress/Groom Compulsion. 2.7093.37 4.9093.41 3.8093.45    p0.16 
PITotal 35.10929.64 43.30930.31 39.20929.48    p0.55 
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; FSIQ, full-scale intelligence quotient; PI, Padua Inventory; PIQ, performance intelligence quotient; VIQ, verbal
intelligence quotient; YBOCS, YaleBrown ObsessiveCompulsive Scale.
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Clinical and neuropsychological assessment
Diagnoses were established using the Structured Clinical Inter-
view for DSM-IV Axis I Disorders, Patient Edition [18]. At the
time of scanning, the patient group reported overall mild to
moderate OCD symptoms (indexed by the YaleBrown Ob-
sessiveCompulsive Scale, YBOCS; characterized by contamina-
tion and checking compulsions; indexed using the Padua Inventory,
PI). Patients were also characterized by moderate cognitive and
affective symptoms of depression and physiological and psycholo-
gical symptoms of anxiety (measured by the Beck Depression
Inventory, BDI-II; and the Beck Anxiety Inventory, BAI). Twelve
of the patients were on stable doses (at least 2 months) of
psychotropic medication at the time of scanning (fluoxetine, n
4; fluvoxamine, n1; citalopram, n2; venlafaxine, n1; clomi-
pramine, n4). Two patients had received adjuvant medications
(e.g. benzodiazepines) within the past 6 months. General intelli-
gence (IQ) was assessed using the Wechsler Abbreviated Scale of
Intelligence (WASI) [19].
1H-MRS imaging acquisition
Magnetic resonance imaging (MRI) data were acquired using
similar methods to those described in our previous studies
[15,20,21]. The previously analysed 1H-MRS data were processed
using a bilateral dorsal ACC voxel of OCD patients to examine its
correlations with haemodynamic responses during cognitive task
performance [15]. We now extend this work in the current analysis
by examining each hemisphere independently, and also by analys-
ing spectra for the rostral ACC, which we have not previously
investigated.
A 3 T GE Signa Horizon LX human imaging scanner (GE
Healthcare, Milwaukee, WI, USA) was used. Subjects were
immobilized, using a Velcro strap (XXX AQ7) over the forehead.
Volume-localized 1H-MRS was recorded from four separate
locations using a standard short-echo point resolved spectroscopy
sequence (TR3000 ms, TE30 ms, with a nominal voxel size of
approx. 6.5 cm3). For the dorsal ACC (dACC) measurements we
acquired 64 transients, whereas rostral ACC (rACC) required 128
transients from each hemisphere due to susceptibility arising from
the ethmoid sinuses, orbits, and vasculature in the region. The
region of interest AQ8(ROI) had to be re-positioned for some
individuals in order avoid major vasculature and to minimize the
influence of this susceptibility. The total scanning time for the 1H-
MRS was approximately 30 min. Figure 1 illustrates the typical
location and spatial geometry of the volume localized voxels.
We measured absolute levels of NAA, Glx, Cr, Cho, and mI
from each of the four volume-localized spectra with LCModel
software [22]. This software utilized a library of reference spectra in
a basis set recorded specifically for the scanner. The LCModel
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Figure 1.AQ9 (a) Functional subdivisions of the anterior cingulate cortex (ACC) on the basis of functional imaging
studies and voxel placements in the current study. The coronal sections through the (A) dorsal ACC (dACC) and
(B) rostral ACC (rACC) regions of interest further highlight the areas of brain coverage by the magnetic resonance
spectroscopy (MRS) voxels. (b) Sample MRS spectrum from the dorsal ACC region highlighting the five main
metabolite peaks: Cho, choline-containing compounds; Cr, creatine plus phosphocreatine; Glx, glutamate
glutamine; NAA, N-acetylaspartate; mI myoinositol-containing compounds. The MRS voxels were placed in each
hemisphere, separated by the medial wall boundary of the frontal lobes, so as to encompass the dACC and rACC.
For the dACC, the posterior boundary of the voxel was approximately 10 mm posterior to a vertical line from the
anterior commissure orthogonal to the anteriorposterior commissure line. The inferior border was approximately
5 mm superior to the top edge of the corpus callosum while the medial border was 12 slices lateral to the
parasagittal slice on the T1 structural image for each hemisphere. For the rACC, the posterior boundary was the
front edge of the corpus callosum while the inferior border was the anteriorposterior commissure line. The medial
border was again 12 slices lateral to the parasagittal slice on the T1 structural image for each hemisphere.
M. YU¨CEL, S.J. WOOD, R.M. WELLARD ET AL. 469
C:/3B2WIN/temp files/IANP305222_S100.3d[x] Monday, 14th April 2008 22:22:9
UN
CO
RR
EC
TE
D P
RO
OF
fitting algorithm uses the multiple peaks contributing to an
individual metabolite spectrum (including macromolecule contri-
bution to the spectra) to estimate the tissue content of each
metabolite [22]. Results are presented in institutional units approx-
imating millimolar concentration (mmol/L), using the tissue water
signal as an internal standard. The residual signal corresponds to,
and is fitted by, additional broad peaks representing unknown
metabolites and components such as macromolecules with short T2
relaxation times.
Statistical analysis
Individual demographic measures of gender, age, education, and
IQ were compared across groups using x2 test and independent
sample t-tests comparing the two groups, in SPSS version 11.0
(SPSSAQ10 , Chicago, IL, USA).
The metabolite content of voxels was corrected for differences in
tissue composition using segmentation information derived from
coronal 3-D spoiled gradient echoAQ11 images recorded during the same
scanning session. The brain component was separated from non-
brain in the structural images, using the Brain Extraction Tool of
FSL (www.fmrib.ox.ac.uk). The images were then segmented into
grey matter (GM), white matter and cerebrospinal fluidAQ12 using the
FAST module of FSL. The proportion (probability) for each of the
three tissue types was then determined for the volume and position
of each MRS voxel, using a module [23] written in IDL for iBrain
(www.brain.org.au/software.html). Where there was a correlation
0.2 (Spearman’s rank-order correlation coefficients, two-tailed)
for the amount of GM in the voxel and any metabolite, we
corrected for the influence of grey matter using a previously
described formula [24], cMRSmMRS  (gradient [mGM 
meanGM]), where cMRS is corrected MRS; mMRS is the
measured MRS concentration; gradient is the gradient of the
regression line between the GM tissue volume of interest and the
average amount of GM in the entire sample of subjects; mGM is
the measured GM fraction; and meanGM is the mean GM tissue
volume of the entire sample. These corrected metabolite concentra-
tions were used for subsequent analyses.
The 1H-MRS parameters used for the present study provided
robust signals for both the healthy control and OCD groups in the
dACC and rACC. Specifically, healthy controls had a dACC and
rACC signal-to-noise ratio of 16.13 (SD2.22) and 14.59 (SD
3.99) and a full width at half maximumAQ13 (FWHM) of 0.06 ppm
(SD0.01) and 0.07 ppm (SD0.02), respectively. OCD patients
had a dACC and rACC signal-to-noise ratio of 16.1 (SD2.8) and
15.7 (SD5.5) and an FWHM of 0.06 ppm (SD0.01) and
0.07 ppm (SD0.03), respectively. None of these measures was
different between the two groups (p0.450.96) suggesting that the
quality of the data is comparable across the two groups. The output
from LCModel includes the CramerRao lower bound, which is a
measure of reliability of the fit. Typically, values B30 are
considered to be reliable for less abundant metabolites such as
mI and Glx, while values B20 are considered to be a good fit for
more abundant metabolites such as NAA, Cr and Cho. Only one
metabolite (mI) for one voxel of a single individual fell well short of
these criteria (i.e. 30) and was entered as ‘missing’. The mean
CramerRao lower bounds (averaged across all regions and hemi-
spheres) for NAA, Cr, Cho, mI and Glx were 5.6, 5.4, 5.9, 10.5 and
10.5 (SD1.87, 1.06, 1.33, 1.99 and 3.06), respectively, for healthy
controls, and 5.8, 5.2, 5.4, 7.7 and 9.7 (SD1.94, 0.92, 1.17, 1.99
and 2.63), respectively, for OCD patients.
Metabolites were analysed individually, using two-way ANOVA
with two repeated measures: hemisphere (left and right) and region
(dACC and rACC). We tested main effects and interactions in the
overall model with a0.05 and examined significant effects with
post-hoc pairwise contrasts evaluated against a Bonferroni-ad-
justed alpha to correct for multiple comparisons. Only effects
involving diagnostic group differences were examined in this
manner because these were the effects of interest in the current
study (as opposed to effects involving hemisphere or region). Effect
sizes, expressed as Cohen’s d [25], are also provided where
appropriate. Spearman’s rank-order correlation coefficients were
used to examine the associations between 1H-MRS metabolite
levels obtained from within each of the ROI and clinical measures
of OCD symptom dimensions and symptom severity. We statisti-
cally covaried for the effects of state-anxiety and depressive
symptomatology in these biochemistry-symptom correlational
analyses. As with previous studies [10], we wanted to investigate
primary OCD symptomatology that could not be explained by
levels of state-related anxiety and depression.
Results
Creatine and choline
There was a significant main effect of hemisphere for both Cr
(F(1,42)9.42; p0.004; d0.44) and choline (F(1,42)9.74;
p0.003; d0.39). No diagnosis effect or interactions with
diagnosis were found for these metabolites. These findings indicate
that across the entire sample, concentrations of both Cr and Cho
were higher in the left hemisphere (Table 2).
Myoinositol
There was a main effect of region (F(1,41)6.99; p0.012; d
0.47) and gender (F(1,41)6.16; p0.017; d0.75), as well as a
hemispherediagnosis interaction (F(1,41)5.10; p0.029, cor-
rected). Post-hoc pairwise contrasts comparing the two groups
within each hemisphere showed that OCD patients had higher
concentrations of mI in the right ACC (collapsed across dorsal and
rostral subregions) compared with healthy controls, although this
just failed to reach significance (F(1,41)3.92; p0.054; d0.62).
N-acetylaspartate
There was a main effect of hemisphere (F(1,42)27.17; pB
0.005; d0.63), and region (F(1,42)43.67; pB0.005; d1.18),
as well as a hemisphereregion interaction (F(1,42)4.15; p
0.04). The main effect of diagnosis trended towards significance
(F(1,42)3.03; p0.089; d0.55).
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Table 2. Metabolite levels for OCD patients and healthy comparison subjects in the dorsal ACC (mean9SD)
‘Metabolite, Hemi-
sphere, Region
OCD patients (n20) Healthy control (n26) Analyses
Male Female Total Male Female Total Main effects Interactions
Cr L DACC 5.5990.34 5.7290.39 5.6690.36 5.8190.33 5.6490.41 5.7290.38 Hemisphere; p0.004
(LeftRight)
RACC 5.6190.29 5.0591.19 5.3390.89 5.4491.21 5.7690.69 5.6090.98
R DACC 5.4890.27 5.4290.44 5.4590.36 5.3990.33 5.4690.39 5.4290.35
RACC 5.3090.86 5.3490.66 5.3290.74 5.0190.97 5.4690.76 5.2390.89
Cho L DACC 1.6790.19 1.5790.24 1.6290.21 1.6590.20 1.5390.21 1.5990.21 Hemisphere; p0.003
(LeftRight)
RACC 1.6990.18 1.4390.42 1.5690.34 1.6290.27 1.6090.28 1.6190.27
R DACC 1.5390.17 1.5390.31 1.5390.26 1.5390.24 1.4390.21 1.4890.21
RACC 1.6490.29 1.5490.31 1.5990.30 1.4790.26 1.4790.28 1.4790.26
NAA L DACC 8.3390.63 7.7390.42 8.0390.60 8.6390.76 8.4390.62 8.5390.69 Hemisphere; pB0.005
(LeftRight) Region;
pB0.005
(dACCrACC)
$Diagnosis;
p0.089 (OCDBHC)
HemisphereRegion;
p0.040
RACC 7.3191.41 6.5191.55 6.9191.50 7.2191.88 7.8991.26 7.5591.60
R DACC 7.7290.57 7.7590.61 7.7490.57 8.1790.98 7.9790.57 8.0790.79
RACC 6.3491.60 6.1891.24 6.2691.40 6.2291.78 6.9291.47 6.5791.64
Glx L DACC 10.1490.90 9.3391.11 9.7491.06 10.1090.81 10.5191.17 10.3191.01 HemisphereRegion
DiagnosisGender;
p0.043
RACC 10.0091.60 9.1991.67 9.5991.65 9.5992.11 10.2291.41 9.9091.79
R DACC 10.2390.85 9.3991.51 9.8191.27 10.5390.84 9.4391.28 9.989120
RACC 9.8992.25 8.6091.01 9.2591.82 9.0992.52 9.8492.11 9.4792.31
mI L DACC 4.3390.73 3.9490.56 4.1390.67 4.2790.65 3.8490.40 4.0590.57 Region; p0.012
(dACCrACC)
Gender; p0.17
(MaleFemale)
HemisphereDiagnosis;
p0.029
RACC 3.9690.44 3.4290.81 3.6990.69 4.0590.65 3.7890.64 3.9190.64
R DACC 4.2590.61 3.8490.63 4.0590.64 3.8690.53 3.6290.47 3.7390.50
RACC 3.9791.20 3.7291.09 3.8491.12 3.5390.77 3.4790.49 3.5090.63
ACC, anterior cingulate cortex; Cho, choline-containing metabolites; Cr, creatinephosphocreatine (Cr); dACC, dorsal ACC; Glu, glutamate; Glx glutamateglutamine; L, left; mI,
myoinositol; NAA, N-acetylaspartateN-acetylaspartylglutamate; OCD, obsessivecompulsive disorder; R, right; rACC, rostral ACC.; Absolute concentrations are expressed as
institutional units approximating mmol/L; $Effect fell short of significance.
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Glutamate and glutamine
There were no main effects of hemisphere, region or gender for
Glx, but there was a four-way hemisphereregiongender
diagnosis interaction (F(1,42)4.37; p0.043). Inspection of the
data and effect size analyses showed that, compared to female
controls, female OCD patients had significantly reduced Glx in all
subregions except the right dACC (Figure 2). Post-hoc analysis of
glutamate alone (after removing metabolite information for two
individuals due to fitting error of 30%) indicated a trend-level
diagnosisgender interaction (F(1,40)3.86; p0.057; d0.58)
indicating that female OCD patients had less overall glutamate
than their healthy counterparts in all ACC subregions.
Effects of psychotropic treatment
Twelve of the OCD patients were receiving some form of
psychotropic therapy at the time of testing, which may have
affected their brain biochemistry. A re-analysis of the data using
repeated-measures ANOVA comparing the 12 medicated OCD
patients to the eight unmedicated patients separately for each
metabolite indicated no significant effects. Due to the small sample
sizes in these comparisons we additionally ran non-parametric tests
(MannWhitney U-test) for each metabolite, none of which
indicated any significant effects, including Glx (p0.16). There
were no significant differences in symptom severity between the
medicated and non-medicated groups.
Biochemical-symptom associations
A correlational analysis was conducted separately for male and
female subjects to determine if the identified patientcontrol
differences in Glx, mI and NAA metabolites were related to
clinical symptom severity and symptom dimensions. These analyses
indicated gender specific (i.e., female only) associations between
ACC biochemistry and OCD symptomatology. Levels of Glx
across the ACC subregions were strongly and positively associated
with OCD symptom severity (particularly the obsessions subscale
and the YBOCS-total score) in female patients (Table 3AQ14 ; Figure 3).
Only the right dACC NAA was correlated with obsession scores;
there were no significant associations for mI in either male or
female subjects.
Discussion
We examined the specificity of brain metabolite
disturbances with respect to gender, hemisphere and
subregion of the ACC in patients with OCD. We
observed a significant reduction in the concentrations
of Glx in all but one of the ACC subregions
investigated in female OCD patients, elevated con-
centrations of mI in the right ACC of both male and
female patients, and a trend towards a global reduc-
tion in NAA in both male and female patients.
Although the mI alterations did not correlate with
any symptom measures, individual differences in
ACC Glx levels in female OCD patients were strongly
correlated with clinical symptom severity, across
nearly all symptom dimensions. There was only a
limited correlation between NAA levels and symptom
measures. The present findings do not represent state-
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Figure 2. AQ15Glutamateglutamine (Glx) concentra-
tions in (a) female and (b) male obsessivecompulsive
disorder (OCD) patients, as well as healthy controls
(HC) across each subregion of the anterior cingulate
cortex (ACC). The left dorsal ACC (dACC) of
female OCD patients was significantly lower in Glx,
compared to their female control counterparts. There
were no significant differences for male OCD patients.
(c) This is further highlighted in the effect size
analysis. Solid black lines, effect size analysis for
glutamate alone.
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related anxiety or depressive symptoms at the time of
scanning because these variables were measured and
statistically controlled in the analyses. Therefore, the
Glx-symptom association identified in female OCD
patients is likely to reflect a more enduring illness
characteristic.
Although others have reported positive correlations
between Glx levels and measures of symptom severity
[7,10], they did not examine gender-related differ-
ences. There is now increasing recognition that
gender may have a significant influence on the clinical
and biological heterogeneity of OCD [17]. For
example, there are slightly more female OCD patients
in adult samples [26]; female patients are more like to
exhibit contamination obsessions and respond better
to treatment [27,28]; and there are sexually dimorphic
patterns of genetic susceptibility [17] including gluta-
mate transporter genes [29] in OCD. In light of the
present findings, future studies should consider more
carefully the putative relationship between gender
and OCD psychopathology.
The present finding of decreased Glx concentra-
tions in OCD patients is consistent with the only
other study to examine this metabolite in the ACC
[11]; but that study, which examined only one
subregion (the rostral ACC) in a paediatric sample,
did not find an effect of gender. Although the Glx
alterations support recent speculations implicating
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Figure 3. Scatterplot of the association between the
YaleBrown ObsessiveCompulsive Scale (YBOCS)-
total score and concentrations of total anterior cingu-
late cortex glutamateglutamine (Glx) for female
obsessivecompulsive disorder patients (the correlation
is partialled for the effects of state anxiety and
depressive symptoms).
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glutamatergic dysfunction in OCD [3032], the direc-
tion of both the present findings and those of
Rosenberg et al. [11] (i.e. decreased rather than
increased) is inconsistent with a straightforward
hyperglutamatergic model and contrasts with the
excessive levels of Glx reported in orbitofrontal and
striatal regions of OCD patients [7,10]. It is unclear
whether Glx alterations reflect explicit changes in
specific physiological processes (e.g. differences in the
cycling of glutamate from neurons to glia, and
anaplerotic metabolism) or cell population (e.g.
differences in the relative distribution of neurons
relative to glia) [33]. This reduced Glx concentration
in the ACC could represent a mechanism for counter-
regulating hyperactivity in the striatum of patients
with OCD. But evidence of a similar pattern of
reduced ACC Glx concentrations in adults and
children with major depressive disorder [11,3436],
together with the absence of these abnormalities in
male OCD patients, suggest that this phenomenon is
not specific to OCD.
OCD patients (both male and female) also had
elevated concentrations of mI in their right ACC.
This metabolite can act as a cerebral osmolyte,
governing processes intrinsic to cellular homeostasis,
such as the accumulation of intracellular water, and
forms a core component of the phosphatidylinositol
second messenger system (PI-cycle) [37]. Abnormal-
ities in cellular mI levels and/or PI-cycle regulation
have been implicated in the pathophysiology and
treatment of OCD, as well as other psychiatric
disorders, including bipolar disorder, major depres-
sive disorder, panic disorder and schizophrenia [38].
As such, this neurochemical abnormality is likely to
reflect a general pathophysiology related to altered
cellular homeostasis, rather than one specific to
OCD.
OCD patients had reduced NAA concentrations,
but a direct comparison with controls fell short of
significance. In our previous analysis of this OCD
group and a subsample of the healthy controls [15],
NAA was reduced, although we did not examine the
rostral ACC and did not investigate the effects of
gender or hemispheric laterality. The failure to
identify a significant difference in the present study
is most likely due to the stringent statistical thresh-
olds used to correct for multiple comparisons. Two
other studies have demonstrated reduced NAA levels
in this region in adult patients [13,14]. NAA is
produced within neuronal mitochondria and is
thought to reflect neuronal density, mitochondrial
metabolism and functional viability [39], but whether
reduced levels reflect neuronal loss or a state of
(potentially reversible) neuronal dysfunction remains
unclear. Interestingly, although NAA abnormalities
in OCD respond to pharmacological treatment [14],
they do not seem to be associated with changes in
symptomatology [8,10,13,14]. One speculation is that
abnormalities in the glutamatergic system are more
relevant to OCD symptomatology, whereas NAA
changes are more closely associated with functional
abnormalities in the region [15]. The lack of signifi-
cant change in other brain metabolites measured by
MRS indicates that processes, such as altered lipid
turnover (choline-containing metabolites), and cellu-
lar energetics (creatine plus phosphocreatine), are
unlikely to be core characteristics of OCD pathophy-
siology.
There are several limitations the present study.
First, we conducted a large number of comparisons
both across and within groups. This was necessary,
given the number of voxels from which we acquired
data, and the number of brain metabolites and
clinical measures investigated. But the analyses were
corrected for multiple comparisons, suggesting that
the findings are robust (also supported by the
relatively large effect sizes). A second limitation was
our focus on the ACC. We did not acquire MRS data
from other brain regions that are also important in
the neurobiology of OCD (e.g. the orbitofrontal
cortex, striatum) [40]. Thus, the anatomical specificity
of the present MRS findings is uncertain. Third, we
examined unresolved Glx with only post-hoc analysis
of glutamate alone for several reasons: (i) the
separation and quantification of glutamate and
glutamine are technically difficult (i.e. overlapping
resonances); (ii) Glx provides a more robust fit
compared with glutamate alone; and (iii) we wanted
to be consistent with previous literature. Neverthe-
less, further 1H-MRS work that separates the gluta-
mate and glutamine signals and also assesses
concentrations of glutathione (a product of glutamate
metabolism that serves as a cellular antioxidant) will
facilitate identification of the physiological processes
associated with the changes in Glx reported here [41].
Finally, despite the fact that we obtained large effects
sizes, some of the analyses (e.g. comparison of
medicated vs unmedicated patients) may have been
underpowered due to the small sample size and/or
confounded by patients receiving adjuvant medica-
tions (e.g. benzodiazepines). In this context, the use of
Bonferroni corrections may have been overly con-
servative, hence we have concurrently reported effect
size statistics to provide an index of the magnitude of
the changes observed. Future studies examining the
relationship between OCD-related biochemical
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changes and how these vary as a function of symptom
profile, treatment history and gender will represent a
useful extension of the present study.
Conclusions
The primary finding is the observation of gender-
specific alterations in ACC Glx in OCD patients.
Importantly, this Glx disturbance is strongly predic-
tive of symptom severity, and is not explained by
levels of state-related anxiety and depressive symp-
toms. Importantly, MRS-detected metabolite ab-
normalities correlate with the severity of OCD-
related impairment, suggesting that this technique
may be of use in objectively monitoring patient
progress and assessing the effectiveness of various
treatments.
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